

????????????????????????????????

????

real-world evidence RWE

real-world study RWS

real-world data RWD

????????????

“ registry” “ ” “ ”

/

patient-focused drug development PFDD

patient experience

data PED

patient-reported outcome PRO

/

8

PRO/ePRO

????????

data model CDM

common

1.??

electronic data capture, EDC EDC

2.????

CDASH Clinical Data Acquisition Standards Harmonization

3.??????

/ /

????????????????????

1.????

PRO

?????????

[Redacted]
 [Redacted]
 [Redacted]
 ALCOA+CCEA [Redacted] ALCOA [Redacted]
 [Redacted]
 [Redacted]

CCEA

?????????????

[Redacted]
 [Redacted]

1.?????

[Redacted]
 [Redacted]
 [Redacted] CDC
 [Redacted]
 [Redacted]
 [Redacted]
 [Redacted]
 [Redacted]
 [Redacted]

2.?????

[Redacted]

- [Redacted]
[Redacted]
- [Redacted]
[Redacted]
[Redacted]
- [Redacted]
[Redacted]

?????????

[Redacted]
 [Redacted]
 [Redacted]

HIS

□□□□	□□
□□□ Registry□	□□□□□□□□□□□□□□□□□□ □□ / □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□
□□□□ Registry-based Study□	□□□□□□□□□□
□□□□ Electronic Medical Record □ EMR)	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□
□□□□□ Observational Study□	□□□□□□□□□□□□□□□□□□ □□□□□□ /□□□□□□□□□□□□
□□□□□ (Patient-reported Outcome, PRO□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□
□□□□□□□□ □ Patient-focused Drug Development □ PFDD)	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□
□□□□□□ Patient Experience Data□ PED/ Patient Input □	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □
□□□□□□□ Retrospective Observational Study□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□
□□□□ Clinical Trial□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□
□□□□ Disease Registry□	□□□□□□□□□□□□□□□□□□
□□□□□□□ Prospective Observational Study□	□□□□□□□□□□□□□□□□□□ / □□□□□□□□□□
□□□□ Data Standard□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□
□□□□ Data Linkage)	□□□□□□□□□□□□□□□□□□ □
□□□□ Data Element□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□
□□□□ Data Curation)	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□
□□□□□□ Common Data Model□ CDM□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□ /□□□□□□□□□□

□□□□	□□
External Control□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□
Source Data□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□
Real-World Data□ RWD□	□□□□□□□□□□□□□□□□□□ / □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□
Real-World Research/Study□ RWR/RWS□	□□□□□□□□□□□□□□□□□□ □ / □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□
Real-World Evidence□ RWE□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ -□□□□□□□□

????????????

□□	□□
□□□□□□	Standard Operating Procedure, SOP
□□□□	Patient Registry
□□□□□□	Single-arm/One-arm Trial
□□	Registry
□□□□	Registry-based Study
□□□□	Electronic Medical Record, EMR
□□□□□□	Observational Study
□□□□□□	Patient Reported Outcome, PRO
□□□□□□□□□□	Patient-focused Drug Development, PFDD
□□□□□□	Patient Experience Data/ Patient Input
□□□□□□□□	Retrospective Observational Study
□□□□	Disease Registry
□□□□□□□□□□	Registry-based/Register-based RCT
□□□□□□□□	Prospective Observational Study
□□□□	Data Standard

[6] FDA. Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products. 2023.12

[7] [REDACTED] . [REDACTED] 2020.8

[8] [REDACTED] . [REDACTED] 2022.1

[9] [REDACTED] . [REDACTED] 2022.6

[10] [REDACTED] . [REDACTED]
2023.3

[11] FDA. Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products (Draft). 2023.2

[12] [REDACTED] . [REDACTED] . 2023.2

[13] [REDACTED] . [REDACTED] . 2016.7

[14] [REDACTED] . [REDACTED] . 2020.7

[15] [REDACTED] . [REDACTED] . 2016.7

[16] [REDACTED] . [REDACTED] . 2023.2

Revision #3

Created 2026-01-15 12:29:37 UTC by Colin Wang

Updated 2026-01-15 12:43:53 UTC by Colin Wang